Opendata, web and dolomites

dreaMS

Digital biomarkers and treatment personalisation in multiple sclerosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "dreaMS" data sheet

The following table provides information about the project.

Coordinator
HEALIOS LLC 

Organization address
address: SEVOGELSTRASSE 32
city: BASEL
postcode: 4052
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://ealios.io
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HEALIOS LLC CH (BASEL) coordinator 50˙000.00

Map

 Project objective

Multiple Sclerosis (MS) diagnosis is based on neurologists’ assessment using a combination of tools: MRI, physical and cognitive assessments and patient reported symptoms. It is well accepted that current tools do not paint a proper picture of the patient illness leading to the need of additional insights into patient symptoms. dreaMS aims to be the 1st digital solution for patient with MS providing digital biomarkers to help with diagnosis, prognosis and treatment choice. The solution supports both patients and providers, allowing for more precise treatment strategies and continuous monitoring, resulting in improved patient outcomes and well-being. Our technology is easy scalable to other diseases treatment (like Alzheimer, schizophrenia, or any neurological illness) The global MS treatment market was valued at $16.13 Billion in 2016, and is expected to reach $27.38 Billion by 2025, driven by the continued uptake of premium products and an increase in treatment rates because of the availability of novel alternatives based on digital solutions. dreaMS will enter to the European digital biomarkers market, which is facing major changes that will reshape the competitive environment for solution vendors and service providers during the coming years. Our key users will be neurologists and MS patients that will use the dreaMS technology. Additionally, because dreaMS benefits among value chain (both users and buyers) we will guarantee a global impact. Phase 1 will center on preparing a feasibility study. This will include the following activities: full identification and characterization of our target market, design of the internationalization and business development strategy, definition of technological needs and product validation, identification and clearance of legal issues and definition of our IPR strategy, and finally, design of the finance strategy and a business plan. We plan to use SMEI-1 to identify interested buyers to take part in demonstrations in SMEI-2.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DREAMS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DREAMS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

Presque (2019)

Smart Nursing Bra

Read More